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The importance of personalized medicine is becoming increasingly recognized. We previously reported a 
wide variability in individual patient propofol requirements for loss of consciousness (LOC) 1. The aim of the 
present study was to identify the physiologic variables that may contribute to the observed inter-individual 
variability.
Data from 217 adult patients submitted to neurosurgical procedures were retrospectively analyzed. Only 
patients submitted to TIVA with propofol and remifentanil were considered. In all cases 1% propofol was 
infused at a slow rate (around 200ml/h), with a TCI pump set to “TCI-view mode”, in order to allow the 
precise identification of the amount required for LOC. LOC was identified as lack of eye opening to name 
calling and a tap on the forehead. Variables considered for analysis were: age, weight, height, lean body 
mass (LBM), gender, ASA status, type of surgery, baseline arterial pressure (systolic, dyastolic and mean), 
baseline heart rate (HR) and baseline BIS value. The amount of propofol (in mg) required for LOC, the 
propofol predicted effect-site concentration (EC in ug/ml) at LOC (Schnider’s PK model), and the induction 
sequence (propofol first or opioid first) were also noted. Multivariate Regression Analysis was used to 
determine if any of the patient data and baseline recordings were predictors of the propofol amount (mg and 
mg/kg) required for LOC, or of the predicted propofol EC at LOC. Data are mean±SD or %.
Data are presented in Table 1 and Figure 1. The propofol EC at LOC ranged from 1.5 to 7.4ug/ml, with an 
IQ range [3.1-5.3] (71%). The total amount of propofol in mg at LOC ranged from 38 to 242mg, with an IQ 
range [71.8-116.3] (62%). Propofol for LOC mg/Kg ranged from 0.6 to 2.9mg/Kg, with an IQ range [1.1-1.7] 
(55%).
The multivariate regression analysis showed as independent predictive factors for the propofol EC at LOC: 
gender (p<0.001) and baseline SAP (p<0.001). These variables explained 25% of the variability (p<0.001). 
For the propofol total amount required for LOC in mg the multivariate regression identified as independent 
predictive factors: age (p<0.001), gender (p=0.018), weight (p=0.009) and baseline SAP (p<0.001). These 
variables explained 31% of the variability (p<0.001). For the propofol total amount in mg/kg the independent 
predictive factors were: age (p<0.001), gender (p=0.045), weight (p<0.001) and baseline SAP (p<0.001). 
These variables explained 30% of the variability (p<0.001). In all models, the female gender and age 
decreased the propofol requirements, while higher SAP baseline values increased the propofol doses.
We show a wide variability in individual patient requirements for propofol to induce LOC, which is critical. 
This variability was observed even when EC were used, although PK models already incorporate gender, 
age, weight and height. Interestingly, the baseline SAP and gender, proved to be independent predictive 
factors and explained at least 25% of the variability. Further research should be directed at identifying the 
physiologic variables that contribute to the observed inter-individual variability.
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